Alpha-defensins : risk factor for thrombosis in COVID-19 infection
© 2021 British Society for Haematology and John Wiley & Sons Ltd..
The inflammatory response to SARS/CoV-2 (COVID-19) infection may contribute to the risk of thromboembolic complications. α-Defensins, antimicrobial peptides released from activated neutrophils, are anti-fibrinolytic and prothrombotic in vitro and in mouse models. In this prospective study of 176 patients with COVID-19 infection, we found that plasma levels of α-defensins were elevated, tracked with disease progression/mortality or resolution and with plasma levels of interleukin-6 (IL-6) and D-dimers. Immunohistochemistry revealed intense deposition of α-defensins in lung vasculature and thrombi. IL-6 stimulated the release of α-defensins from neutrophils, thereby accelerating coagulation and inhibiting fibrinolysis in human blood, imitating the coagulation pattern in COVID-19 patients. The procoagulant effect of IL-6 was inhibited by colchicine, which blocks neutrophil degranulation. These studies describe a link between inflammation and the risk of thromboembolism, and they identify a potential new approach to mitigate this risk in patients with COVID-19 and potentially in other inflammatory prothrombotic conditions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:194 |
|---|---|
| Enthalten in: |
British journal of haematology - 194(2021), 1 vom: 28. Juli, Seite 44-52 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abdeen, Suhair [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.07.2021 Date Revised 14.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bjh.17503 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM326017356 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM326017356 | ||
| 003 | DE-627 | ||
| 005 | 20240214232317.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.17503 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1292.xml |
| 035 | |a (DE-627)NLM326017356 | ||
| 035 | |a (NLM)34053084 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abdeen, Suhair |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Alpha-defensins |b risk factor for thrombosis in COVID-19 infection |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.07.2021 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 British Society for Haematology and John Wiley & Sons Ltd. | ||
| 520 | |a The inflammatory response to SARS/CoV-2 (COVID-19) infection may contribute to the risk of thromboembolic complications. α-Defensins, antimicrobial peptides released from activated neutrophils, are anti-fibrinolytic and prothrombotic in vitro and in mouse models. In this prospective study of 176 patients with COVID-19 infection, we found that plasma levels of α-defensins were elevated, tracked with disease progression/mortality or resolution and with plasma levels of interleukin-6 (IL-6) and D-dimers. Immunohistochemistry revealed intense deposition of α-defensins in lung vasculature and thrombi. IL-6 stimulated the release of α-defensins from neutrophils, thereby accelerating coagulation and inhibiting fibrinolysis in human blood, imitating the coagulation pattern in COVID-19 patients. The procoagulant effect of IL-6 was inhibited by colchicine, which blocks neutrophil degranulation. These studies describe a link between inflammation and the risk of thromboembolism, and they identify a potential new approach to mitigate this risk in patients with COVID-19 and potentially in other inflammatory prothrombotic conditions | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 infection | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a interleukin-6 | |
| 650 | 4 | |a thrombosis | |
| 650 | 4 | |a α-defensins | |
| 650 | 7 | |a Fibrin Fibrinogen Degradation Products |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Tubulin Modulators |2 NLM | |
| 650 | 7 | |a alpha-Defensins |2 NLM | |
| 650 | 7 | |a fibrin fragment D |2 NLM | |
| 650 | 7 | |a Colchicine |2 NLM | |
| 650 | 7 | |a SML2Y3J35T |2 NLM | |
| 700 | 1 | |a Bdeir, Khalil |e verfasserin |4 aut | |
| 700 | 1 | |a Abu-Fanne, Rami |e verfasserin |4 aut | |
| 700 | 1 | |a Maraga, Emad |e verfasserin |4 aut | |
| 700 | 1 | |a Higazi, Mohamed |e verfasserin |4 aut | |
| 700 | 1 | |a Khurram, Nigar |e verfasserin |4 aut | |
| 700 | 1 | |a Feldman, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Deshpande, Charuhas |e verfasserin |4 aut | |
| 700 | 1 | |a Litzky, Leslie A |e verfasserin |4 aut | |
| 700 | 1 | |a Heyman, Samuel N |e verfasserin |4 aut | |
| 700 | 1 | |a Montone, Kathleen T |e verfasserin |4 aut | |
| 700 | 1 | |a Cines, Douglas B |e verfasserin |4 aut | |
| 700 | 1 | |a Higazi, Abd Al-Roof |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d 1955 |g 194(2021), 1 vom: 28. Juli, Seite 44-52 |w (DE-627)NLM000000396 |x 1365-2141 |7 nnns |
| 773 | 1 | 8 | |g volume:194 |g year:2021 |g number:1 |g day:28 |g month:07 |g pages:44-52 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bjh.17503 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 194 |j 2021 |e 1 |b 28 |c 07 |h 44-52 | ||